Rangering i aksjer
#39190
hVIVO plc (HVO) operates as a premier full-service Contract Research... hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical development services to a wide-ranging and growing client base, which includes seven of the world's ten largest biopharmaceutical companies. A key specialisation for hVIVO is orchestrating human challenge trials across numerous infectious and respiratory diseases, utilising its advanced, London-based quarantine facility, the largest of its kind globally. Additionally, the company offers extensive virology and immunology laboratory services through its hLAB division. Through its German subsidiary, CRS, hVIVO manages a 120-bed capacity across sites in Mannheim and Kiel, delivering early-phase clinical trial expertise, including first-in-human and proof-of-concept studies. Its other subsidiary, Venn Life Sciences, contributes to the biopharma sector by providing specialist early drug development consulting and biometry services. The Group collectively offers integrated drug development solutions, covering stages from preclinical research up to Phase II trials, supported by patient recruitment via FluCamp. Moreover, its five clinical sites facilitate outpatient Phase II and III trials, ensuring a streamlined and effective transition from drug discovery to late-stage development.
Pris HVO pris med markedsverdi på B
Markedsverdi av HVIVO plc(HVO)
Markedsverdi: $609.98K
Per August 2026 har HVIVO plc en markedsverdi på $609.98K. Dette gjør HVIVO plc til det 39190th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for HVIVO plc fra 2012 til 2026
HVO sammenlignet med topp 5 mest populære stocks
| Pris på HVO |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.470T
|
+896,668,417.49%
|
|
|
|
|
$4.467T
|
+732,325,422.91%
|
|
|
|
|
$4.174T
|
+684,343,072.41%
|
|
|
|
|
$3.700T
|
+606,585,496.51%
|
|
|
|
|
$2.854T
|
+467,936,925.15%
|
